BIO Comments on FDA Public Workshop on Patient-Focused Drug Development: Guidance 1
February 16, 2018
BIO submitted comments after the Food and Drug Administration’s (FDA) public hearings on Patient-Focused Drug Development: Guidance 1 – Collecting Comprehensive and Representative Input.
BIO commends the FDA’s efforts to facilitate the use of patient experience data (PED) for medical product development and regulatory decision-making. Flexibility and openness to innovative methods and practices will be important as new ideas and approaches emerge every day.
While BIO agrees the patient-focused drug development (PFDD) guidance documents should complement the FDA guidance on patient-reported outcomes (PRO), the PRO guidance is too restrictive and has not led to an increase in qualified or validated PRO tools for use in labeling. BIO asks FDA to keep the PFDD guidance documents broadly applicable and flexible. BIO’s comments include answers to the FDA’s questions and suggestions on how to clarify and improve the PFDD guidance.
Download Full Comments Below
BIO Letter Patient-Focused Drug Development Guidance 1 Collecting Comprehensive And Representative Input FDA2017-N-5896
Under the 340B program, participating manufacturers must offer 340B pricing on their covered outpatient drugs by covered entities, as a condition of having those drugs federally payable under Medicare Part B and Medicaid. Critically, Congress…
BIO submitted these comments in response to the United States Patent and Trademark Office’s May 10, 2024, Notice of Proposed Rulemaking regarding Terminal Disclaimer Practice to Obviate Nonstatutory Double Patenting.
BIO submitted comments after the Food and Drug Administration’s (FDA) public hearings on Patient-Focused Drug Development: Guidance 1 – Collecting Comprehensive and Representative Input.
BIO commends the FDA’s efforts to facilitate the use of patient experience data (PED) for medical product development and regulatory decision-making. Flexibility and openness to innovative methods and practices will be important as new ideas and approaches emerge every day.
While BIO agrees the patient-focused drug development (PFDD) guidance documents should complement the FDA guidance on patient-reported outcomes (PRO), the PRO guidance is too restrictive and has not led to an increase in qualified or validated PRO tools for use in labeling. BIO asks FDA to keep the PFDD guidance documents broadly applicable and flexible. BIO’s comments include answers to the FDA’s questions and suggestions on how to clarify and improve the PFDD guidance.